CGVHD 2024


Call for Abstracts

Abstract Submission is Now OPEN

The Abstract Submission portal for cGvHD 2024 is now open. Please click on the button below to submit your abstract.

Abstract Submission Guidelines

Authors are asked to present their work with precise and clear objectives, directly related to their evidence and scientific support to support their research or clinical study. The Executive Committee and the Scientific Board of the Congress will evaluate each abstract presented.

  • Abstracts are accepted in English only
  • The maximum word limit for Abstract title is 20 (excluding spaces)
  • The maximum word limit for Abstract text is 300 + 1 image or table (excluding spaces) or 350 with no images or tables (excluding spaces)
  • 1 image or table is equal to 50 words
  • Abstracts submitted via email or paper are not accepted
  • There can be only 1 Presenting Author
  • The maximum number of Co-authors is 10
  • There is no limit to the number of abstracts submitted by an Author
  • Required sections for Abstract submission: Introduction, Methods, Results, Conclusion
  • Submitting an abstract does not register you for cGVHD 2024
  • If your abstract is accepted as Oral Presentation or Poster you will be entitled to a discounted rate (rates to be disclosed in Mid May)

Your research might tackle one or more of the following themes:

  • Chronic Graft-versus-Host Biomarkers
  • Biology and pathophysiology of cGvHD
  • Clinical evaluation of cGvHD and measurement of disease 
  • Clinical management approaches for cGvHD 
  • Clinical trials in the treatment or prevention of cGvHD
  • Advocacy for resources to support the care and research in cGvHD
  • Support of cGvHD patients, family and care takers
  • Long term outcomes and treatment of patients with cGvHD
  • Regulatory aspects of cGvHD treatment
  • All authors must complete a conflict of interest declaration during their abstract submission (no form necessary)
  • If your research has been granted any commercial support, you will be asked to disclose this during the submission process

Instructions for Writing and Submitting Abstracts

We invite fellows/people in training who would like to present an oral/poster presentation to submit an abstract for consideration by the Scientific Committee. Abstracts must be submitted in one of the following categories:

  1. Chronic GvHD – preclinical/basic research
  2. Chronic GvHD – clinical research
  3. Supportive care and quality of life.

Complete abstracts must be submitted online no later than 5PM in your local time zone on the deadline date.  The Scientific Committee will determine whether the abstract will be accepted for an oral presentation. Those not accepted for an oral presentation will be considered for a poster. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission to the Congress agency, and of all communications thereafter.

Copyright Statement: Authors of each abstract retain the copyright for their own abstracts.

Formatting Instructions

Language: The abstract must be written in English. Your submission should be edited to ensure clear communication of your work.

  • Topic Selection: All abstract submissions must be submitted under one of the categories listed in the guidelines.
  • Presentation Format: Please indicate your primary preference regarding abstract presentation format, either oral or as a poster.
  • Word Count: Total length of abstract must not exceed 500 words.  The submission title is not included in this count.
  • Title format: Title must be sentence case with no period at the end
  • Authors & Institutions: Please enter all abstract authors in order from subordinate to superior.  The presenting author must be listed first. Please be sure to include first and last name. The initials of any middle names can be added. List each organization in full (no abbreviations). 
  • Sections: Abstracts should include the following sections: Background, Purpose, Methods, Results, and Conclusions. 
  • Acronyms/Abbreviations: These should be defined the first time they appear. Eg. hematopoietic cell transplantation (HCT).
  • Figures: One (1) figure and/or one (1) table is permitted.  If included, figure must be of sufficiently high resolution with a concise and editable title and caption underneath. Tables must be fully editable and presented in MS Word format. 
  • Links: When making reference to a webpage, use the full clickable link and include date accessed or posted.

Frequently Asked Questions

Are case reports considered for abstracts?
No, we do not allow the submission of case reports.

Does cGVHD accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations in the introduction section of the abstract.

When will I receive the Notification Letter?
Notification Letters will be sent in early August

I am having trouble submitting my abstract – what can I do?
If you have questions or troubles, please email at

Important Dates

March 25, 2024

Early Registration Opens

May 16, 2024

Abstracts Submissions Open

August 5, 2024

Abstract Submission Deadline

August 16, 2024

Abstract Notifications

August 15, 2024

Early Registration Deadline

September 29, 2024

Accommodation Booking Deadline

October 9, 2024 

Registration Deadline